Search Results - "Kailajärvi, M."

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment by KEMPPAINEN, N. M, AALTO, S, PARKKOLA, R, RINNE, J. O, WILSON, I. A, NAGREN, K, HELIN, S, BRÜCK, A, OIKONEN, V, KAILAJÄRVI, M, SCHEININ, M, VIITANEN, M

    Published in Neurology (08-05-2007)
    “…Patients with mild cognitive impairment (MCI) have increased risk to develop Alzheimer disease (AD). In AD increased brain amyloid burden has been demonstrated…”
    Get full text
    Journal Article
  2. 2

    Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease by KEMPPAINEN, N. M, AALTO, S, PARKKOLA, R, RINNE, J. O, WILSON, I. A, NAGREN, K, HELIN, S, BRÜCK, A, OIKONEN, V, KAILAJÄRVI, M, SCHEININ, M, VIITANEN, M

    Published in Neurology (14-11-2006)
    “…PET studies with N-methyl-[(11)C]2-(4':-methylaminophenyl)-6-hydroxybenzothiazole ([(11)C]PIB) have revealed an increased tracer uptake in several brain…”
    Get full text
    Journal Article
  3. 3

    Reminders of Drug Effects on Laboratory Test Results by Kailajarvi, Marita, Takala, Timo, Gronroos, Paula, Tryding, Nils, Viikari, Jorma, Irjala, Kerttu, Forsstrom, Jari

    Published in Clinical chemistry (Baltimore, Md.) (01-09-2000)
    “…Drug effects on laboratory test results are difficult to take into account without an online decision support system. In this study, drug effects on hormone…”
    Get full text
    Journal Article Conference Proceeding
  4. 4
  5. 5

    Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa by Kuoppamäki, M, Sauramo, A, Korpela, K, Vahteristo, M, Kailajärvi, M, Lehtinen, T, Ellmén, J

    “…Controlled-release levodopa/carbidopa (CR-LC) is often used to provide prolonged control of night-time motor symptoms in patients with Parkinson's disease…”
    Get full text
    Journal Article
  6. 6

    Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids by Kailajärvi, M, Ahokoski, O, Virtanen, A, Salminen, E, Irjala, K

    Published in Anticancer research (01-03-2000)
    “…Tamoxifen is widely used as an adjuvant treatment for breast cancer. To correctly interpret laboratory test results during tamoxifen treatment, clinicians…”
    Get more information
    Journal Article
  7. 7

    Early effects of 5-fluorouracil, epirubicin and cyclophosphamide therapy on common laboratory tests by Kailajärvi, M, Ahokoski, O, Virtanen, A, Salminen, E, Irjala, K

    Published in Anticancer research (01-07-2001)
    “…Combination chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) is now used for adjuvant therapy of breast cancer. The effects of FEC on…”
    Get more information
    Journal Article
  8. 8

    Assessment of MAO‐B Occupancy in the Brain With PET and [11C]‐L‐Deprenyl‐D2: A Dose‐Finding Study With a Novel MAO‐B Inhibitor, EVT 301 by Hirvonen, J, Kailajärvi, M, Haltia, T, Koskimies, S, Någren, K, Virsu, P, Oikonen, V, Sipilä, H, Ruokoniemi, P, Virtanen, K, Scheinin, M, Rinne, JO

    Published in Clinical pharmacology and therapeutics (01-05-2009)
    “…Inhibition of monoamine oxidase type B (MAO‐B) activity in the brain is a putative strategy for the treatment of Alzheimer's disease (AD). We performed a…”
    Get full text
    Journal Article
  9. 9

    Alterations in laboratory test results during adjuvant breast cancer treatment by Kailajärvi, M, Ahokoski, O, Virtanen, A, Salminen, E, Irjala, K

    Published in Clinical chemistry and laboratory medicine (01-05-2000)
    “…An increasing number of women is treated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy for breast cancer. The effects of the…”
    Get more information
    Journal Article
  10. 10

    Frequency and clinical outcome of potentially harmful Drug metabolic interactions in patients hospitalized on internal and pulmonary medicine wards : Focus on warfarin and cisapride by LAINE, Kari, FORSSTRÖM, Jari, GRÖNROOS, Paula, IRJALA, Kerttu, KAILAJÄRVI, Marita, SCHEININ, Mika

    Published in Therapeutic drug monitoring (01-10-2000)
    “…Drug metabolic interactions present potential risks in patient care, but their frequency and relative importance as a clinical problem remains unclear. To…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13
  14. 14